Hürthle cell carcinoma: current perspectives.
Repository Usage Stats
Hürthle cell carcinoma (HCC) can present either as a minimally invasive or as a widely invasive tumor. HCC generally has a more aggressive clinical behavior compared with the other differentiated thyroid cancers, and it is associated with a higher rate of distant metastases. Minimally invasive HCC demonstrates much less aggressive behavior; lesions <4 cm can be treated with thyroid lobectomy alone, and without radioactive iodine (RAI). HCC has been observed to be less iodine-avid compared with other differentiated thyroid cancers; however, recent data have demonstrated improved survival with RAI use in patients with HCC >2 cm and those with nodal and distant metastases. Patients with localized iodine-resistant disease who are not candidates for a wait-and-watch approach can be treated with localized therapies. Systemic therapy is reserved for patients with progressive, widely metastatic HCC.
SubjectHurthle cell lesion
follicular cell carcinoma
minimally invasive HCC
Published Version (Please cite this version)10.2147/OTT.S119980
Publication InfoAhmadi, Sara; Stang, Michael; Jiang, Xiaoyin Sara; & Sosa, Julie Ann (2016). Hürthle cell carcinoma: current perspectives. Onco Targets Ther, 9. pp. 6873-6884. 10.2147/OTT.S119980. Retrieved from https://hdl.handle.net/10161/15141.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
More InfoShow full item record
Assistant Professor of Medicine
Associate Professor of Pathology
I am a pathologist specializing in cytopathology and surgical pathology. I diagnose diseases through integrating clinical history and studying patient samples under the microscope. As a cytopathologist, I perform fine needle aspiration biopsies in our clinic. I serve as Chief of the Head and Neck Service, and Director of the Duke Pathology Communications Group. My research interests focus on the pathology of the head and neck and endocrine systems, with particular interest in thyro
Julie Ann Sosa
Professor of Surgery
Julie Ann Sosa, MD MA FACS is Chief of Endocrine Surgery at Duke University and leader of the endocrine neoplasia diseases group in the Duke Cancer Institute and the Duke Clinical Research Institute. She is Professor of Surgery and Medicine. Her clinical interest is in endocrine surgery, with a focus in thyroid cancer. She is widely published in outcomes analysis, as well as cost-effectiveness analysis, meta-analysis, and survey-based research, and she is director of health services research for
Michael Tracey Stang
Associate Professor of Surgery
Alphabetical list of authors with Scholars@Duke profiles.
Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info